Page 113 - 《中国药房》2025年2期
P. 113

XIONG  F,GUO  H,CHEN  M  L,et  al.  Influence  of   2017,39(4):422-428.
              CYP2C19  gene  polymorphism  on  unbound  plasma  con‐  [30]  CHEN X M,XIAO Y H,LI H P,et al. Therapeutic drug
              centrations of voriconazole in patients with invasive fun‐  monitoring  and  CYP2C19  genotyping  guide  the  applica‐
              gal  infections[J].  Chin  J  Pharm  Anal,2019,39(2):  tion of voriconazole in children[J]. Transl Pediatr,2022,
              291-295.                                            11(8):1311-1322.
          [25]  孙钰珊. 采用伏立康唑抗真菌治疗的肝硬化患者血清伏                    [31]  FAN  X  H,ZHANG  H,WEN  Z  P,et  al.  Effects  of
              立康唑谷浓度分布特征及影响因素[J/OL]. 中国肝脏病                        CYP2C19,CYP2C9  and  CYP3A4  gene  polymorphisms
              杂志(电子版),2018,10(3):86-89[2024-04-30]. https://      on plasma voriconazole levels in Chinese pediatric patients
              kns. cnki. net/kcms2/article/abstract? v=ifIT5_n5_GekUb6-  [J]. Pharmacogenet Genomics,2022,32(4):152-158.
              mXAZGxFUMlT-49Csk9QTZzh8JawoVwNh7mgf2hsCi-     [32]  WANG T T,ZHU H F,SUN J Y,et al. Efficacy and safety
              0TM9TNetBf69U7-emyKgPwnMwLQQBraELaYsqOoE9e-         of  voriconazole  and  CYP2C19  polymorphism  for  opti‐
              knP-QOFIpjUzx_RYtvvI3lIldYJIi4ISRNhVwbHCrZoK1a-     mised dosage regimens in patients with invasive fungal in‐
              FpwX2-BR_Xkc0mJUowB-xVxt7_foSmN_yfzZ8DvL21_         fections[J]. Int J Antimicrob Agents,2014,44(5):436-442.
              oDiA&uniplatform=NZKPT&language=CHS. DOI:10.   [33]  赵婷,沈皓,张惠兰,等. 新疆维吾尔族异基因造血干细
              3969/j.issn.1674-7380.2018.03.016.                  胞移植高危患儿的伏立康唑血浆谷浓度的分布特征及
              SUN Y S. Distribution characteristics and influencing fac‐  对疗效和不良反应的影响[J]. 中国医院药学杂志,2022,
              tors of valley concentration of serum voriconazole in liver   42(23):2505-2510,2544.
              cirrhosis patients who underwent antifungal therapy with   ZHAO T,SHEN H,ZHANG H L,et al. Distribution cha-
              voriconazole[J/OL].  Chin  J  Liver  Dis  Electron  Version,  racteristics of voriconazole plasma trough concentration in
              2018,10(3):86-89[2024-04-30].  https://kns. cnki. net/  Xinjiang Uygur children at high risk of allogeneic hemato‐
              kcms2/article/abstract?v=ifIT5_n5_GekUb6mXAZGxFUMlT-  poietic stem cell transplantation and its effect on efficacy
              49Csk9QTZzh8JawoVwNh7mgf2hsCi0TM9TNetBf69U7-        and  adverse  reactions  of  voriconazole[J].  Chin  J  Hosp
              emyKgPwnMwLQQBraELaYsqOoE9e-knP-QOFIpjUzx_          Pharm,2022,42(23):2505-2510,2544.
              RYtvvI3lIldYJIi4ISRNhVwbHCrZoK1aFpwX2-BR_X-    [34]  CHUWONGWATTANA S,JANTARAROUNGTONG T,
              kc0mJUowB-xVxt7_foSmN_yfzZ8DvL21_oDiA&unipla-       PROMMAS  S,et  al.  Impact  of  CYP2C19,CYP3A4,
              tform=NZKPT&language=CHS. DOI:10.3969/j.issn.1674-  ABCB1,and FMO3 genotypes on plasma voriconazole in
              7380.2018.03.016.                                   Thai  patients  with  invasive  fungal  infections[J].  Pharma‐
          [26]  王百乔,赵震宇,韩敏,等. 伏立康唑治疗侵袭性真菌感                        col Res Perspect,2020,8(6):e00665.
              染致肝损伤影响因素及 CYP2C19 基因多态性[J]. 中华                [35]  ZENG  G  T,WANG  L  L,SHI  L  H,et  al.  Variability  of
              医院感染学杂志,2021,31(13):1957-1962.                      voriconazole  concentrations  in  patients  with  hemato-
              WANG B Q,ZHAO Z Y,HAN M,et al. Influencing fac‐     poietic stem cell transplantation and hematological malig‐
              tors  for  invasive  fungal  infection-induced  liver  injury  in   nancies:influence  of  loading  dose,procalcitonin,and
              patients  treated  with  voriconazole  and  CYP2C19  gene   pregnane X receptor polymorphisms[J]. Eur J Clin Phar‐
              polymorphisms[J]. Chin J Nosocomiology,2021,31(13):  macol,2020,76(4):515-523.
              1957-1962.                                     [36]  ALLEGRA S,FATIGUSO G,FRANCIA S,et al. Pharma‐
          [27]  李敏,周丽娟,张华,等. CYP2C19基因多态性对侵袭性                     cogenetic of voriconazole antifungal agent in pediatric pa‐
              真菌感染患者伏立康唑用药的指导意义探讨[J]. 中国医                         tients[J]. Pharmacogenomics,2018,19(11):913-925.
              院药学杂志,2020,40(2):156-160,207.                  [37]  ZHANG  Y,HOU  K  L,LIU  F,et  al.  The  influence  of
              LI M,ZHOU L J,ZHANG H,et al. The significance of    CYP2C19 polymorphisms on voriconazole trough concen‐
              CYP2C19  gene  polymorphism  in  guiding  voriconazole     trations:systematic  review  and  meta-analysis[J].  Mycoses,
              administration  in  patients  with  invasive  fungal  infection  2021,64(8):860-873.
              [J]. Chin J Hosp Pharm,2020,40(2):156-160,207.  [38]  GUYOT  C,HOFSTETTER  L,STIEGER  B.  Differential
          [28]  EBRAHIMPOUR S,NAMAZI S,MOHAMMADI M,et             effects  of  membrane  cholesterol  content  on  the  transport
              al. Impact of CYP2C19 polymorphisms on serum concen‐  activity  of  multidrug  resistance-associated  protein  2
              tration  of  voriconazole  in  Iranian  hematological  patients  (ABCC2)and of the bile salt export pump(ABCB11)[J].
              [J]. J Res Pharm Pract,2017,6(3):151-157.           Mol Pharmacol,2014,85(6):909-920.
          [29]  LI Z W,PENG F H,YAN M,et al. Impact of CYP2C19              (收稿日期:2024-07-31  修回日期:2024-11-30)
              genotype and liver function on voriconazole pharmacoki‐                             (编辑:陈 宏)
              netics in renal transplant recipients[J]. Ther Drug Monit,



          中国药房  2025年第36卷第2期                                                 China Pharmacy  2025 Vol. 36  No. 2    · 231 ·
   108   109   110   111   112   113   114   115   116   117   118